Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase 1 7Phase 3 4Phase 1/2 4Phase EARLY_PHASE1 2Phase 4 2Phase NA 1

Status

Recruiting 2Completed 2

Sponsor Class

OTHER 191NIH 109NETWORK 108INDUSTRY 102OTHER_GOV 4UNKNOWN 2

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 2Plasma cell 1Other hematologic neoplasm 1

Conditions

Breast Neoplasms 2Neoplasms 1Multiple Myeloma 1Leukemia, Myeloid, Acute 1Leukemia 1

Interventions

Radiotherapy 10Cisplatin 9Carboplatin 7Capecitabine 6Neoadjuvant Therapy 5Gemcitabine 5Fluorouracil 5Docetaxel 5Paclitaxel 4Cyclophosphamide 4Trastuzumab 3Tamoxifen 3Surgical Procedures, Operative 3Oxaliplatin 3Hydralazine 3Etoposide 3Drug Therapy 3pertuzumab 2pegylated granulocyte colony-stimulating factor 2palbociclib 2endostar protein 2Valproic Acid 2Tranexamic Acid 2Temozolomide 2TP protocol 2Saline Solution 2Radiotherapy, Adjuvant 2Radiation 2Proton Pump Inhibitors 2Pemetrexed 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × OTHER_GOV × Cyclophosphamide × Clear all
NCT05477589 2024-12-19

SCRIPT-AML

Vastra Gotaland Region

Phase 3 Recruiting
170 enrolled
Other hematologic neoplasm

Leukemia, Neoplasms, Leukemia, Myeloid, Acute

NCT06520176 2024-07-25

Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients

The Affiliated People's Hospital of Ningbo University

Phase 3 Recruiting
99 enrolled
Plasma cell

Multiple Myeloma

NCT02995772 2019-06-19

Neoadjuvant Hormonal Therapy Compared to Neoadjuvant Chemotherapy in Stage IIIB/C and IV Breast Cancer Patients

Dharmais National Cancer Center Hospital

Phase 3 Completed
122 enrolled
Breast

Breast Neoplasms

NCT00352378 2011-06-27

Primary Chemotherapy With Adriamycin/Cyclophosphamide(AC) vs Taxotere/Xeloda(TX) for Stage II and III Breast Cancer

National Cancer Center, Korea

Phase 3 Completed
209 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡